Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
5.62
+0.07 (1.26%)
Nov 28, 2025, 4:00 PM EST - Market closed
Karyopharm Therapeutics Employees
Karyopharm Therapeutics had 279 employees as of December 31, 2024. The number of employees decreased by 46 or -14.15% compared to the previous year.
Employees
279
Change (1Y)
-46
Growth (1Y)
-14.15%
Revenue / Employee
$510,860
Profits / Employee
-$446,670
Market Cap
95.83M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 279 | -46 | -14.15% |
| Dec 31, 2023 | 325 | -60 | -15.58% |
| Dec 31, 2022 | 385 | -57 | -12.90% |
| Dec 31, 2021 | 442 | 10 | 2.31% |
| Dec 31, 2020 | 432 | 85 | 24.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KPTI News
- 25 days ago - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 25 days ago - Karyopharm Therapeutics Inc. (KPTI) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 25 days ago - Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress - PRNewsWire
- 4 weeks ago - Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025 - PRNewsWire
- 7 weeks ago - Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 2026 - Benzinga
- 7 weeks ago - Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis - PRNewsWire
- 2 months ago - Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis - PRNewsWire
- 3 months ago - Karyopharm Therapeutics Inc. (KPTI) Q2 2025 Earnings Call Transcript - Seeking Alpha